“Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma”, Hematol Meeting Rep, vol. 2, no. 5, Jun. 2009, doi: 10.4081/hmr.v2i5.736.